Payment overview · 2025
General Payments
$466.35
23 reported records · 7 companies
Healthcare provider profile · identity verified
Traci L Hoatson, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · NORTH PLATTE, NE · NPI 1174618458
Verified facts
What the public records show
CMS Open Payments records show Traci L Hoatson, APRN received $466.35 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 43.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $203.77 | 43.7% | 9 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $78.24 | 16.8% | 4 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $73.07 | 15.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $60.22 | 12.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.12 | 4.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.47 | 4.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.46 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $466.35 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $150.10 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $150.10 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $78.24 | 4 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $73.07 | 4 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $60.22 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $53.67 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 166 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 27 |
| Losartan Potassium | Losartan Potassium | 138 | 22 |
| Meloxicam | Meloxicam | 122 | 23 |
| Gabapentin | Gabapentin | 107 | 20 |
| Clonazepam | Clonazepam | 100 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 17 |
| Famotidine | Famotidine | 95 | 17 |
| Potassium Chloride | Potassium Chloride | 87 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | suppressed |
| Omeprazole | Omeprazole | 65 | 17 |
| Tramadol Hcl | Tramadol Hcl | 65 | 13 |
| Ozempic | Semaglutide | 64 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 11 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Furosemide | Furosemide | 59 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 15 |
| Trazodone Hcl | Trazodone Hcl | 57 | 12 |
| Lamotrigine | Lamotrigine | 51 | 13 |
| Torsemide | Torsemide | 51 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 49 | 12 |
| Glipizide | Glipizide | 48 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | 13 |
| Pregabalin | Pregabalin | 46 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | suppressed |
| Prednisone | Prednisone | 44 | 20 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 38 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 14 |
| Lisinopril | Lisinopril | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 34 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Metformin Hcl | Metformin Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Carvedilol | Carvedilol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 11 |
| Baclofen | Baclofen | 20 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Azithromycin | Azithromycin | 16 | 14 |
| Cephalexin | Cephalexin | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Simvastatin | Simvastatin | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Eliquis | Apixaban | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $466.35 · 23 records | ABBVIE INC. | CAPLYTA, Jornay PM, NURTEC ODT, QULIPTA, REXULTI, SPRAVATO, UBRELVY, UZEDY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error